135 related articles for article (PubMed ID: 28829515)
1. Oxycodone-induced neurotoxicity secondary to concurrent voriconazole use in a patient with cancer.
Alghothani L; Gustin J
J Opioid Manag; 2017; 13(3):141-142. PubMed ID: 28829515
[TBL] [Abstract][Full Text] [Related]
2. [Opioid overdose following voriconazole treatment - case report].
Ingason AB; Magnusson MK; Ragnarsson GB
Laeknabladid; 2019 Juli; 105(7):335-337. PubMed ID: 31411569
[No Abstract] [Full Text] [Related]
3. Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey.
Watanabe M; Homma M; Momo K; Okoshi Y; Wada T; Hara A; Chiba S; Kohda Y
Eur J Clin Pharmacol; 2011 Aug; 67(8):859-61. PubMed ID: 21221960
[No Abstract] [Full Text] [Related]
4. Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2011 Aug; 67(8):863-4. PubMed ID: 21221959
[No Abstract] [Full Text] [Related]
5. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
6. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
8. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
Fanelli G; Fanelli A
Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study.
Cuomo A; Russo G; Esposito G; Forte CA; Connola M; Marcassa C
Am J Hosp Palliat Care; 2014 Dec; 31(8):867-76. PubMed ID: 24249829
[TBL] [Abstract][Full Text] [Related]
10. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
Clemens KE; Quednau I; Klaschik E
Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
[TBL] [Abstract][Full Text] [Related]
11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
12. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
Hermanns K; Junker U; Nolte T
Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
[TBL] [Abstract][Full Text] [Related]
13. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
[TBL] [Abstract][Full Text] [Related]
14. Respiratory depression related to multiple drug-drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone.
Charpiat B; Tod M; Darnis B; Boulay G; Gagnieu MC; Mabrut JY
Eur J Clin Pharmacol; 2017 Jun; 73(6):787-788. PubMed ID: 28280888
[No Abstract] [Full Text] [Related]
15. How I treat pain in hematologic malignancies safely with opioid therapy.
Geyer HL; Gazelka H; Mesa R
Blood; 2020 Jun; 135(26):2354-2364. PubMed ID: 32352512
[TBL] [Abstract][Full Text] [Related]
16. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
Mercadante S; Giarratano A
Expert Opin Investig Drugs; 2013 Jan; 22(1):161-6. PubMed ID: 23215628
[TBL] [Abstract][Full Text] [Related]
17. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
[TBL] [Abstract][Full Text] [Related]
18. Ultra-High-Dose Opioids With Low Efficacy and Significant Harm-Time to Make a Change: A Teachable Moment.
Guillod P; Edens EL; Becker WC
JAMA Intern Med; 2017 Jan; 177(1):17-18. PubMed ID: 27893881
[No Abstract] [Full Text] [Related]
19. Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients.
Yamada T; Kanazawa Y; Aoki Y; Uchida E
J Nippon Med Sch; 2015; 82(2):100-5. PubMed ID: 25959201
[TBL] [Abstract][Full Text] [Related]
20. Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain.
Ray WA; Chung CP; Murray KT; Hall K; Stein CM
JAMA; 2016 Jun; 315(22):2415-23. PubMed ID: 27299617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
